MISSISSAUGA, ON, Nov. 11 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for the first quarter of fiscal 2010, ended September 30, 2009.

"During our first fiscal quarter, we continued to advance our lead drug nimotuzumab, which is being developed globally through a network of cooperative relationships. We enrolled the first patients in our YM-sponsored multinational, randomized, Phase II double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer (NSCLC) and continued to enroll patients in our randomized Phase II trial of nimotuzumab in NSCLC patients ineligible for radical chemotherapy. The US Treasury Department cleared YM's subsidiary, YM BioSciences USA Inc., of any limitations in clinical trials in the US for nimotuzumab in cancer indications and we are proposing to add US centers to these trials and potentially other trials being conducted by our licensees if and when cleared by the FDA," said David Allan, Chairman and CEO of YM BioSciences.

Subsequent to the end of the quarter we announced our proposal to merge Cytopia Ltd., an Australian clinical-stage drug development company, into YM. We believe Cytopia's lead products hold significant unrecognized potential and will benefit from YM's clinical and regulatory expertise and our access to the US capital markets," added Mr. Allan. Cytopia's lead products are CYT997, a novel, orally-available vascular disrupting agent (VDA) currently in Phase II trials, and CYT387, a novel, orally-active JAK1/2 inhibitor that recently received clearance from the FDA to commence a Phase I trial in myeloproliferative disorders which is planned to be initiated at Mayo Clinic in this current quarter. The meeting of Cytopia shareholders to vote on this transaction is scheduled to occur in January 2010.


    Nimotuzumab is currently being evaluated in 32 Phase II and III clinical
trials, 11 of which are being conducted by YM's majority owned subsidiary,
CIMYM BioSciences Inc., or its licensees.

    -   Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in Japan,
        and YM's licensee in Korea, Kuhnil Pharmaceutical Co., are currently
        collaborating on a randomized, open-label Phase II trial evaluating
        nimotuzumab plus irinotecan compared to irinotecan alone in patients
        with advanced or recurrent gastric cancer refractory to 5-FU-
        containing regimens which is reportedly expected to complete
        recruitment in calendar 2009. Daiichi Sankyo is also conducting a
        Phase II trial in first-line NSCLC for which completion of
        recruitment is reportedly expected in the first half of 2010.

    -   YM initiated randomized, double-blind Phase II, trials in patients
        with brain metastases from non-small cell lung cancer (NSCLC) and in
        NSCLC patients ineligible for radical chemotherapy. Recruitment
        commenced in Canada in March 2009 for palliative NSCLC and in
        September for the brain metastases trial. A Phase II, second-line,
        single-arm trial in children with progressive diffuse intrinsic
        pontine glioma (DIPG) is ongoing at multiple sites in the US, Canada,
        and Israel.

    -   Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported
        completion of recruitment in a single-arm, Phase III trial of
        nimotuzumab as first-line therapy for DIPG in August 2007, and the
        preliminary data from this trial that was released at ASCO in 2008
        was expanded on at the annual international pediatric oncology forum,
        SIOP, held in São Paulo, Brazil in October 2009. OSAG advises that,
        based on the data it plans to submit a Pediatric Investigation Plan
        (PIP) to the EMEA forthwith which, if approved by the Pediatric
        Committee (PDCO) would support a submission for marketing
        authorization. OSAG reports that it continues to recruit in a Phase
        III trial in adult glioma patients and a Phase IIb/III trial in
        pancreatic cancer patients.

    -   Innogene Kalbiotech PTE Ltd. (IGK), CIMYM's licensee in South East
        Asia, has reportedly received marketing approval for nimotuzumab in
        the Philippines and Indonesia and in January 2009, the National
        Cancer Centre of Singapore announced that it was launching a
        worldwide Phase III, 710-patient trial of nimotuzumab in the post-
        operative or adjuvant setting in head and neck cancer. This trial is
        in addition to the on-going investigator-initiated Phase II trial in
        locally advanced head and neck cancer and the initiation of a Phase
        II trial in cervical cancer being conducted by IGK.

    -   Nimotuzumab reportedly received approval for marketing in Mexico,
        bringing to 23 the number of countries that are now reported as
        having approved the drug for sale in specific indications.

For calendar 2010, YM BioSciences anticipates an extensive roll-out of important data concerning nimotuzumab's clinical utility and continued differentiation from the other marketed drugs in its class. Anticipated clinical data for calendar 2010 include:

    -   Final Phase III pediatric glioma data (Europe)
    -   Phase III adult glioma data (Europe)
    -   Phase II pediatric glioma data (North America)
    -   Phase II gastric cancer data (Japan)
    -   Phase II first-line non-small cell lung cancer data (Japan)
    -   Phase II esophageal data (Brazil)


YM continues to prepare its second late-stage product, AeroLEF(R), for further development internationally. After consulting with regulatory bodies in Europe and Canada, YM is now determining the optimal clinical path forward and conducting discussions with prospective partners around the Phase III strategy.

Financial Results (CDN dollars)

Total revenue for the first quarter of fiscal 2010, ended September 30, 2009 was $0.7 million compared to $1.7 million for the first quarter of fiscal 2009, ended September 30, 2008. Revenue from licensees was $0.7 million for first quarter of fiscal 2010 compared to $1.2 million for the first quarter of fiscal 2009. Interest income for the first quarter of fiscal 2010 was $19,000 compared with $443,000 for the first quarter of fiscal 2009.

The majority of YM's out-licensing revenue comes from five out-licensing agreements with third party licensees. Revenue decreased mainly because the recognition period for the initial payments for the Daiichi Pharmaceutical Co., Ltd. and Kuhnil Pharmaceuticals Co., Ltd. contracts were extended by 12 months effective January 1, 2009 as a result of a revision to the estimated periods of these collaborations, and revenue from the Innogene Kalbiotech Private Limited contract was fully recognized in the quarter ended December 2008. YM also began receiving royalty payments from a limited sales program in Europe starting in the fourth quarter of fiscal 2008.

Licensing and product development expenses were $2.4 million for the first quarter of fiscal 2010 compared to $3.8 million for the first quarter of fiscal 2009. The decrease was due to lower development costs associated with nimotuzumab and AeroLEF(TM) described below, and lower salaries and travel expenses as a result of a reduction of staff in YM`s U.S. office.

Costs associated with development activities for nimotuzumab were $0.8 million for the three months ended September 30, 2009 compared to $1.0 million for the three months ended September 30, 2008. Expenses in the first quarter for fiscal 2010 were related to two new YM-sponsored clinical trials, one for brain metastases from non-small cell lung cancer (NSCLC) and the other for NSCLC patients ineligible for radical chemotherapy, which were initiated during the third quarter of fiscal 2009, as well as the ongoing pediatric glioma trial.

Costs associated with development activities for AeroLEF(R) were $0.4 million for the three months ended September 30, 2009 compared to $0.5 million for the three months ended September 30, 2008. The decrease was primarily due to the shift from clinical activity to marketing and out-licensing initiatives. The expenses for the current quarter were primarily for ongoing product stability, patents, and out-licensing activities.

General and administrative expenses were $1.8 million for the first quarter of fiscal 2010 compared with $1.1 million for the first quarter of fiscal 2009. This increase was mainly attributed to higher stock-based compensation expenses as well as an increase in legal and consulting fees related to the search for and assessment of new products for potential acquisition.

Net loss for the first quarter of fiscal 2010 was $3.5 million ($0.06 per share) compared to $3.2 million ($0.06 per share) for the same period last year.

As at September 30, 2009, the Company had cash and short-term deposits totaling $39.5 million and accounts payables and accrued liabilities totaling $1.6 million compared to $42.1 million and $0.9 million respectively at June 30, 2009. Management believes that the cash and short-term deposits at September 30, 2009 are sufficient to support the Company's activities for at least the next twelve months.

As at September 30, 2009 the Company had 58,225,458 common shares outstanding, of which 2,380,953 shares are held in escrow to be released contingent upon the completion of certain milestones.

Notice of AGM and mailing

YM BioSciences' Annual and Special Meeting of Shareholders will be held on November 19th, 2009 at 4:00 p.m. at the Gallery of the TSX Broadcast & Conference Centre, The Exchange Tower, 130 King Street West, Toronto, Ontario.

The management proxy circular documents and annual financial documents have been mailed to shareholders and are available online at www.ymbiosciences.com, www.edgar.com and www.sedar.com.

Cancellation of AIM Listing

YM also announced that trading of the Company's Common Shares on the AIM market of the London Stock Exchange ("AIM") was cancelled on October 26, 2009. YM shares had traded on AIM since 2002, however the majority of YM's shareholder base and liquidity now result from its Canadian and US listings. Therefore YM concluded that the additional costs associated with maintaining a listing on AIM were not justifiable given its North American focused shareholder base. The cancellation of trading of its common shares on AIM was effective at 7:00 a.m. (GMT) on Monday, October 26, 2009 (the "Cancellation Date").

Following the cancellation of the Company's Common Shares on AIM, shareholders may continue to hold their shares and may continue to trade such shares on either the TSX under the symbol 'YM' or the NYSE Amex under the symbol 'YMI'. YM does not expect the liquidity or marketability of its common shares to be materially affected by the AIM delisting.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Summary financial statements attached:

    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars,
     unless otherwise noted)

                                                September 30,        June 30,
                                                        2009            2009


    Current assets:
      Cash                                     $  34,269,093   $   2,337,716
      Short-term deposits                          5,205,955      39,713,042
      Accounts receivable                            439,911         564,584
      Prepaid expenses                               231,488         352,850
                                                  40,146,447      42,968,192

    Property and equipment                            84,187          96,876

    Intangible assets                              2,739,732       3,004,868

                                               $  42,970,366   $  46,069,936
    Liabilities and Shareholders' Equity

    Current liabilities:
      Accounts payable                         $     674,216   $     431,028
      Accrued liabilities                            878,174         486,723
      Deferred revenue                             2,557,955       2,549,568
                                                   4,110,345       3,467,319

    Deferred revenue                               2,250,416       2,898,292

    Shareholders' equity:
      Share capital                              172,940,340     172,921,153
      Contributed surplus                         13,424,004      13,035,123
      Deficit                                   (149,754,739)   (146,251,951)
                                                  36,609,605      39,704,325

    Basis of presentation
    Subsequent event

                                               $  42,970,366   $  46,069,936

    Interim Consolidated Statements of
     Operations and Comprehensive Loss and Deficit
    (Expressed in Canadian dollars, unless otherwise noted)

                                                      Three months ended
                                                          September 30,
                                                        2009            2008
    Out-licensing revenue                      $     727,538   $   1,214,945
    Interest income                                   19,119         442,621
                                                     746,657       1,657,566

      Licensing and product development            2,436,048       3,845,184
      General and administrative                   1,784,432       1,147,378
                                                   4,220,480       4,992,562

    Loss before the undernoted                    (3,473,823)     (3,334,996)
    Gain (loss) on foreign exchange                  (26,747)         12,203
    Loss on short-term deposits                       (2,218)       (140,559)
    Other income                                           -         307,140

    Loss and comprehensive
     loss for the period                          (3,502,788)     (3,156,212)

    Deficit, beginning of period                (146,251,951)   (133,182,485)

    Deficit, end of period                     $(149,754,739)  $(136,338,697)

    Basic and diluted loss per common share    $       (0.06)  $       (0.06)


    Weighted average number of common
     shares outstanding                           55,844,505      55,835,356

    Excludes common shares held in
     escrow for contingent additional
     payment related to the acquisition
     of Delex Therapeutics Inc.                    2,380,953       2,380,953


    Interim Consolidated Statements of Cash Flows
    (Expressed in Canadian dollars, unless otherwise noted)

                                                    Three months ended
                                                       September 30,
                                                        2009            2008

    Cash provided by (used in):

    Operating activities:
      Loss for the period                      $  (3,502,788)  $  (3,156,212)
      Items not involving cash:
        Amortization of property and equipment        16,252          18,631
        Amortization of intangible assets            265,136         265,136
        Loss on short-term deposits                    2,218         140,559
        Stock-based compensation                     396,644         190,333
      Change in non-cash operating
       working capital:
        Accounts receivable and
         prepaid expenses                            246,035        (109,840)
        Accounts payable, accrued liabilities
         and deferred revenue                         (4,850)       (683,008)
                                                  (2,581,353)     (3,334,401)

    Financing activities:
      Issue of common shares on
       exercise of options                            11,424               -

    Investing activities:
      Short-term deposits, net                    34,504,869      13,200,126
      Additions to property and equipment             (3,563)        (12,704)
                                                  34,501,306      13,187,422

    Increase in cash                              31,931,377       9,853,021

    Cash, beginning of period                      2,337,716       3,119,189

    Cash, end of period                        $  34,269,093   $  12,972,210

%SEDAR: 00004652E

SOURCE Gilead Sciences, Inc.

For further information: For further information: Enquiries: James Smith, the Equicom Group Inc., Tel. (416) 815-0700 x 229, Email: jsmith@equicomgroup.com; Thomas Fechtner, the Trout Group LLC, Tel. (646) 378-2931, Email: tfechtner@troutgroup.com; Nominated Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050 6500

Organization Profile

Gilead Sciences, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890